LONG-TERM REAL-WORLD COMPARISON OF IL-17A AND TNF-Α INHIBITION IN ANKYLOSING SPONDYLITIS: SECUKINUMAB VS INFLIXIMAB
Keywords:
To compare the long-term efficacy and safety of intravenous Secukinumab (150 mg) versus Infliximab in patients with AS over a 24-month follow-up period.Abstract
Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton that leads to pain, stiffness, and progressive structural damage. Biologics targeting TNF-α and IL-17A have revolutionized treatment. While Infliximab remains a widely used TNF inhibitor, Secukinumab, an IL-17A inhibitor, is increasingly considered an alternative. Real-world head-to-head data remain limited.
References
1.2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. https://doi.org/10.1136/annrheumdis-2016-210770
2.Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. https://doi.org/10.1056/nejmoa1505066
Downloads
Published
2026-10-17